Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: A study from the German-Austrian acute myeloid leukemia study group

Journal of Clinical Oncology

Volumn 29, Issue 19, 2011, Pages 2709-2716

  Krönke, Jan ^a   Schlenk, Richard F ^a   Jensen, Kai Ole ^a   Tschürtz, Florian ^a   Corbacioglu, Andrea ^a   Gaidzik, Verena I ^a   Paschka, Peter ^a   Onken, Shiva ^a   Eiwen, Karina ^a   Habdank, Marianne ^a   Späth, Daniela ^a   Lübbert, Michael ^b   Wattad, Mohammed ^c   Kindler, Thomas ^d   Salih, Helmut R ^e   Held, Gerhard ^f   Nachbaur, David ^l   Von Lilienfeld Toal, Marie ^g   Germing, Ulrich ^h   Haase, Detlef ⁱ   Mergenthaler, Hans Günther ^j   Krauter, Jürgen ^k   Ganser, Arnold ^k   Göhring, Gudrun ^k   Schlegelberger, Brigitte ^k   Döhner, Hartmut ^a   Döhner, Konstanze ^a   more..

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Evangelic Hospital Essen Werden   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

^g UNIVERSITY OF BONN   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF GÖTTINGEN   (Germany)

^j KLINIKUM STUTTGART   (Germany)

^k HANNOVER MEDICAL SCHOOL   (Germany)

^l UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOPHOSMIN; RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AUSTRIA; BLOOD SAMPLING; BONE MARROW; CANCER MORTALITY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GENE MUTATION; GERMANY; HUMAN; INCIDENCE; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AUSTRIA; BONE MARROW; DNA MUTATIONAL ANALYSIS; FEMALE; GERMANY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM, RESIDUAL; NUCLEAR PROTEINS; PROGNOSIS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79960127726     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.0371     Document Type: Conference Paper

References (32)

1. Freeman SD, Jovanovic JV, Grimwade D: Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol 35:388-400, 2008
2. Döhner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
3. Müller MC, Cross NC, Erben P, et al: Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23:1957-1963, 2009
4. Brüggemann M, Raff T, Flohr T, et al: Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107:1116-1123, 2006 (Pubitemid 43156313)
5. Esteve J, Escoda L, Martin G, et al: Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): Benefit of an early intervention. Leukemia 21:446-452, 2007
6. Grimwade D, Jovanovic JV, Hills RK, et al: Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 27:3650-3658, 2009
7. Corbacioglu A, Scholl C, Schlenk RF, et al: Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol 28:3724-3729, 2010
8. Perea G, Lasa A, Aventin A, et al: Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 20:87-94, 2006
9. Scholl C, Schlenk RF, Eiwen K, et al: The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Haematologica 90:1626-1634, 2005 (Pubitemid 41814986)
10. Falini B, Mecucci C, Tiacci E, et al: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266, 2005 (Pubitemid 40110814)
11. Schnittger S, Schoch C, Kern W, et al: Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739, 2005 (Pubitemid 41739006)
12. Döhner K, Schlenk RF, Habdank M, et al: Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106:3740-3746, 2005 (Pubitemid 41739007)
13. Verhaak RG, Goudswaard CS, van Putten W, et al: Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106:3747-3754, 2005 (Pubitemid 41739008)
14. Schlenk RF, Döhner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358: 1909-1918, 2008
15. Falini B, Nicoletti I, Martelli MF, et al: Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): Biologic and clinical features. Blood 109:874-885, 2007 (Pubitemid 46220630)
16. Gorello P, Cazzaniga G, Alberti F, et al: Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 20:1103-1108, 2006 (Pubitemid 43797304)
17. Chou WC, Tang JL, Wu SJ, et al: Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 21:998-1004, 2007
18. Papadaki C, Dufour A, Seibl M, et al: Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: Clonal evolution is a limiting factor. Br J Haematol 144:517-523, 2009
19. Schnittger S, Kern W, Tschulik C, et al: Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 114:2220-2231, 2009
20. Dvorakova D, Racil Z, Jeziskova I, et al: Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations. Am J Hematol 85:926-929, 2010
21. Stahl T, Badbaran A, Kröger N, et al: Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: Comparison of peripheral blood and bone marrow analysis. Leuk Lymphoma 51:1837-1843, 2010
22. Thiede C, Creutzig E, Illmer T, et al: Rapid and sensitive typing ofNPM1mutations using LNA-mediated PCR clamping. Leukemia 20:1897-1899, 2006
23. Schlenk RF, Döhner K, Mack S, et al: Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian Trial AMLHD98A. J Clin Oncol 28:4642-4648, 2010
24. Beillard E, Pallisgaard N, van der Velden VH, et al: Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): A Europe Against Cancer program. Leukemia 17:2474-2486, 2003
25. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
26. Gray R: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
27. Korn EL: Censoring distributions as a measure of follow-up in survival analysis. Stat Med 5:255-260, 1986
28. Harrell F: Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY, Springer Verlag, 2001
29. R Development Core Team: R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2009
30. Cilloni D, Renneville A, Hermitte F, et al: Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J Clin Oncol 27:5195-5201, 2009
31. Ommen HB, Schnittger S, Jovanovic JV, et al: Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1 and CBFB-MYH11 acute myeloid leukemias Blood 115:198-205, 2009
32. Suzuki T, Kiyoi H, Ozeki K, et al: Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 106:2854-2861, 2005 (Pubitemid 41510764)